Hamostaseologie 2010; 30(02): 73-81
DOI: 10.1055/s-0037-1617046
Review
Schattauer GmbH

The importance of quality assurance in molecular genetic laboratories

Die Bedeutung qualitäts sichernder Maßnahmen in der molekular biologischen Labordiagnostik
C. Mannhalter
1   Klinisches Institut für Medizinische und Chemische Labordiagnostik, Medizinische Universität Wien, Österreich
› Author Affiliations
Further Information

Publication History





Publication Date:
30 December 2017 (online)

Summary

Several challenges arise from the wide application of molecular genetic analyses, among them the need to introduce rules to evaluate molecular genetic test systems as well as test laboratories. This article specifically addresses laboratories performing molecular genetic tests for diagnosis, prevention and therapy of various diseases. The topics that will be discussed will support these laboratories to achieve and sustain a high quality and avoid mistakes and errors. The article covers important preanalytic, analytic and postanalytic aspects in regard to molecular genetic testing as well as quality management issues. In addition laboratory responsibilities, training of personnel, data protection issues, as well as informed consent aspects will be discussed. Beyond that, some molecular genetic methods will be dealt with in regard to potential quality criteria.

Zusammenfassung

Aus dem recht breiten Einsatz der molekularbiologischen Analytik ergeben sich eine Reihe von Herausforderungen wie z. B. die Notwendigkeit der Einführung von Regeln zur Überprüfung der Qualität der Tests sowie der Testlabors. Die nachstehenden Ausführungen des Artikels richten sich speziell an Labors, die genetische Untersuchungen zur Diagnose, Behandlung und Prävention von Erkrankungen einsetzen. Die vorgestellten Themen sollen zur Sicherstellung einer hohen Qualität von genetischen Testlabors und zur Vermeidung von Fehlern beitragen. Es werden wichtige präanalytische, analytische und postanalytische Aspekte sowie das Qualitätsmanagement der molekulargenetischen Diagnostik besprochen. Darüber hinaus werden Laborverantwortlichkeiten, Ausbildung des Personals, Datenschutz sowie Aufklärung bzw. Einverständnis der Patienten zum Test diskutiert. Weiters wird kurz auf molekulargenetische Testmethoden und deren Anforderungen eingegangen.

 
  • Literatur

  • 1 Andersson HC, Krousel-Wood MA, Jackson KE. et al. Medical genetic test reporting for cystic fibrosis (deltaF508) and factor V Leiden in North American laboratories. Genet Med 2002; 4: 324-327.
  • 2 Bonini P, Plebani M, Ceriotti F, Rubboli F. Errors in laboratory medicine. Clin Chem 2002; 48: 691-698.
  • 3 Carraro P, Plebani M. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem 2007; 53: 1338-1342.
  • 4 Chen B, Gagnon MB, Shahangian S. et al. Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions. Morbidity and Mortality Weekly Report 2009; 58: 1-37.
  • 5 Clinical and Laboratory Standards Institute.. Application of a quality management system model for laboratory services; approved guideline. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; Publication no. GP26-A3; 2004
  • 6 CLSI Document.. Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods. MM13-P, Vol. 25, No. 9, 2005.
  • 7 Dorn-Beineke A, Ahmad-Nejad P, Pfeiffer U. et al. Improvement of technical and analytical performance in DNA sequencing by external quality assessment-based molecular training. Clin Chem 2006; 52: 2072-2078.
  • 8 GeneTests.. Medical genetics information resource. www.genetests.org.
  • 9 Giardiello FM, Brensinger JD, Petersen GM. et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 1997; 336: 823-827.
  • 10 Hofgartner WT, Tait JF. Frequency of problems during clinical molecular-genetic testing. Am J Clin Pathol 1999; 112: 14-21.
  • 11 Hudson KL, Murphy JA, Kaufman DJ. et al. Oversight of US genetic testing laboratories. Nature Bio-technology 2006; 24: 1083-1090.
  • 12 Kroese M, Zimmern RL, Farndon P. et al. How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network. Eur J Hum Genet 2007; 15: 917-921.
  • 13 Ledbetter DH, Faucett WA. Issues in genetic testing for ultra-rare diseases: background and introduction. Genet Med 2008; 10: 309-313.
  • 14 McGovern MM, Benach MO, Wallenstein S. et al. Quality assurance in molecular genetic testing laboratories. JAMA 1999; 281: 835-840.
  • 15 McGovern MM, Benach M, Wallenstein S. et al. Personnel standards and quality assurance practices of biochemical genetic testing laboratories in the United States. Arch Pathol Lab Med 2003; 127: 71-76.
  • 16 McGovern MM, Elles R, Beretta I. et al. Report of an international survey of molecular genetic testing laboratories. Community Genet 2007; 10: 123-131.
  • 17 Moore CA, Khoury MJ, Bradley LA. From genetics to genomics: using gene-based medicine to prevent disease and promote health in children. Semin Perinatol 2005; 29: 135-143.
  • 18 Myers MF, Chang MH, Jorgensen C. et al. Genetic testing for susceptibility to breast and ovarian cancer: evaluating the impact of a direct-to-consumer marketing campaign on physicians’ knowledge and practices. Genet Med 2006; 8: 361-370.
  • 19 Parsons PJ, Reilly AA, Esernio-Jenssen D. et al. Evaluation of blood lead proficiency testing: comparison of open and blind paradigms. Clin Chem 2001; 47: 322-330.
  • 20 Pintao MC, Garcia AA, Borgel D. et al. Gross deletions/duplications in PROS1 are relatively common in point mutation-negative hereditary protein S deficiency. Hum Genet 2009; 126: 449-456.
  • 21 Plebani M. Errors in clinical laboratories or errors in laboratory medicine?. Clin Chem Lab Med 2006; 44: 750-759.
  • 22 Schunkert H, Konig IR, Erdmann J. Molecular signatures of cardiovascular disease risk: potential for test development and clinical application. Mol Diagn Ther 2008; 12: 281-287.
  • 23 Spector EB, Grody WW, Matteson CJ. et al. Technical standards and guidelines: venous thromboembolism (factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 2005; 7: 444-453.
  • 24 Walder K, Segal D, Jowett J. et al. Obesity and diabetes gene discovery approaches. Curr Pharm Des 2003; 9: 1357-1372.
  • 25 Yoon PW, Chen B, Faucett A. et al. Public health impact of genetic tests at the end of the 20th century. Genet Med 2001; 3: 405-410.